Portable nanofluidic aptamer-SERS instrument for measurement of chemical exposure

用于测量化学暴露的便携式纳米流体适体-SERS 仪器

基本信息

  • 批准号:
    8431721
  • 负责人:
  • 金额:
    $ 24.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-19 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Project Summary The goal of this NIH-SBIR Phase I proposal is to develop a new point-of-care (POC) detection platform and methodology for assessment of human exposure to hazardous environmental compounds in the bloodstream. Because the mechanisms of transport of such chemicals into the body, their differing stabilities, and elimination are difficult to model, if possible, it is much more straightforward to assay for these compounds in the body rather than in the environment. The primary innovations in our approach are that a novel optical micro- to nano-fluidic device will be used along with unique aptamers and Raman reporter molecules to simultaneously measure several classes of compounds in a multiplexed fashion. The opto-fluidic device is an extremely sensitive surface enhanced Raman spectroscopy (SERS) nanochannel cartridge that was invented at Texas A&M University by professors Jun Kameoka and Gerard Cot¿. The aptamer functionalization chemistry as well as the overall integrated product will be developed at BioTex, Inc. The device being developed provides signal enhancements equal to or exceeding 1014 at the entrance to the nanochannel, enabling rapid quantification of femtomolar or smaller levels of targets in fluids. This SERS-based nanofluidic platform has been demonstrated through several publications and so the key question that need to be addressed by the company are can the aptamer chemistry perform as intended in progressively complex media including whole blood with this platform and can the platform be optimized for this application. Thus, the specific aims of this research are to develop the aptamer assay for specifically detecting model polychlorinated biphenyls (PCBs), bisphenol-A (BPA), and model phthalates. The resonant-SERS reporting and nanofluidic concentrator employed have the potential to provide orders-of-magnitude improved sensitivity over standard fluorescence and without the complicated multistep tasks of ELISA or full analytical chemistry analysis such as chromatography and mass spectrometry. PUBLIC HEALTH RELEVANCE: Project Narrative The goal of this research is to develop a new point-of-care (POC) detection platform and methodology for assessment of biological exposure to harmful chemical compounds. With the potential to greatly improve the sensitivity and ease of such measurements, the end-product of this research is expected to have considerable impact allowing toxicologists, environmental health professionals, and clinicians the ability to correlate the effects of toxic chemicals to disease states.
项目概述NIH-SBIR第一阶段提案的目标是开发一种新的护理点(POC)检测平台和方法,用于评估人类对血液中有害环境化合物的暴露。由于这些化学物质进入体内的运输机制、它们不同的稳定性和消除很难建模,如果可能的话,在体内而不是在环境中分析这些化合物要简单得多。我们方法的主要创新是,将使用一种新颖的光学微到纳米流体设备与独特的适配子和拉曼报告分子一起以多路复用的方式同时测量几类化合物。这种光流控设备是一种极其灵敏的表面增强拉曼光谱(SERS)纳米通道盒,由德克萨斯A&M大学教授Jun Kameoka和Gerard Cot?发明。适体官能化化学以及整体集成产品将由BioTex公司开发。正在开发的设备在纳米通道的入口处提供等于或超过1014的信号增强,从而能够快速定量流体中的毫微摩尔或更小水平的靶。这个基于SERS的纳米流体平台已经通过多份出版物进行了演示,因此该公司需要解决的关键问题是适体化学能否在使用该平台的包括全血在内的日益复杂的介质中发挥预期的作用,以及该平台能否针对这一应用进行优化。因此,本研究的具体目的是建立一种能够特异性检测模型多氯联苯(PCbs)、双酚A(BPA)和模型邻苯二甲酸酯的适体分析方法。采用的共振SERS报告和纳米流体浓缩器有可能提供比标准荧光提高数量级的灵敏度,并且不需要复杂的多步骤任务的酶联免疫吸附试验或全分析化学分析,如层析和质谱学。 公共卫生相关性:项目简介这项研究的目标是开发一种新的护理点(POC)检测平台和方法,用于评估有害化合物的生物暴露。由于有可能极大地提高此类测量的敏感性和易用性,这项研究的最终产品预计将产生相当大的影响,使毒理学家、环境卫生专业人员和临床医生能够将有毒化学物质的影响与疾病状态相关联。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

George W Jackson其他文献

George W Jackson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('George W Jackson', 18)}}的其他基金

Aptamer engineering of lentiviral vectors for cardiac gene therapies
用于心脏基因治疗的慢病毒载体适体工程
  • 批准号:
    10759105
  • 财政年份:
    2023
  • 资助金额:
    $ 24.89万
  • 项目类别:
Bench-top Reader and Aptamer-based Assay for Rapid, High-sensitivity Drug/Opiate Detection
用于快速、高灵敏度药物/阿片类药物检测的台式读数仪和基于适体的检测
  • 批准号:
    10760088
  • 财政年份:
    2023
  • 资助金额:
    $ 24.89万
  • 项目类别:
Rapid, Quantitative Point-of-Care Measurement of Tuberculosis Treatment Adherence
快速、定量的护理点测量结核病治疗依从性
  • 批准号:
    10065420
  • 财政年份:
    2020
  • 资助金额:
    $ 24.89万
  • 项目类别:
Neonatal Opioid Screening Using Aptamers and Compensated Interferometry
使用适体和补偿干涉测量法进行新生儿阿片类药物筛查
  • 批准号:
    10216688
  • 财政年份:
    2019
  • 资助金额:
    $ 24.89万
  • 项目类别:
Neonatal Opioid Screening Using Aptamers and Compensated Interferometry
使用适体和补偿干涉测量法进行新生儿阿片类药物筛查
  • 批准号:
    10226376
  • 财政年份:
    2019
  • 资助金额:
    $ 24.89万
  • 项目类别:
SBIR, PA16-302, Point-of-care aptamer-based surface enhanced Raman scattering (aptamer-SERS) detection of malaria metabolites in urine and saliva
SBIR,PA16-302,基于适体的表面增强拉曼散射(适体-SERS)检测尿液和唾液中的疟疾代谢物
  • 批准号:
    9410126
  • 财政年份:
    2017
  • 资助金额:
    $ 24.89万
  • 项目类别:
Portable nanofluidic aptamer-SERS instrument for measurement of chemical exposure
用于测量化学暴露的便携式纳米流体适体-SERS 仪器
  • 批准号:
    8981629
  • 财政年份:
    2012
  • 资助金额:
    $ 24.89万
  • 项目类别:
Rapid Microbial Identification by MALDI-TOF Mass Spectrometry of Ribosomal RNA
通过核糖体 RNA 的 MALDI-TOF 质谱法快速鉴定微生物
  • 批准号:
    8059006
  • 财政年份:
    2010
  • 资助金额:
    $ 24.89万
  • 项目类别:
Platform for Massively Parallel Selection of Aptamer Ligands
适体配体大规模并行选择平台
  • 批准号:
    8338877
  • 财政年份:
    2009
  • 资助金额:
    $ 24.89万
  • 项目类别:
Platform for Massively Parallel Selection of Aptamer Ligands
适体配体大规模并行选择平台
  • 批准号:
    7745690
  • 财政年份:
    2009
  • 资助金额:
    $ 24.89万
  • 项目类别:

相似海外基金

Hyer Power - Hydrogen extended range Powertrain for Special Purpose vehicles including Ambulances, Fire Engines and Road Sweepers
Hyer Power - 适用于救护车、消防车和道路清扫车等特殊用途车辆的氢增程动力系统
  • 批准号:
    10045909
  • 财政年份:
    2023
  • 资助金额:
    $ 24.89万
  • 项目类别:
    BEIS-Funded Programmes
Sterilising equipment for hospitals, ambulances and schools
医院、救护车和学校的设备消毒
  • 批准号:
    69652
  • 财政年份:
    2020
  • 资助金额:
    $ 24.89万
  • 项目类别:
    Feasibility Studies
Development of an electrostatic sprayer device to be utilised for environmental decontamination in the Healthcare Estate and Ambulances and Transport
开发静电喷雾装置,用于医疗保健区、救护车和运输中的环境净化
  • 批准号:
    69980
  • 财政年份:
    2020
  • 资助金额:
    $ 24.89万
  • 项目类别:
    Feasibility Studies
Influence of inappropriate calls made to 119 on arrival time of ambulances at the emergency scene for severe or moderate patients in Osaka city, Japan
日本大阪市不当拨打119对重度或中度患者急救现场救护车到达时间的影响
  • 批准号:
    15K19250
  • 财政年份:
    2015
  • 资助金额:
    $ 24.89万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Optimal transport route of ambulances depending on patient's clinical condition and urgency
根据患者的临床状况和紧急程度确定救护车的最佳运输路线
  • 批准号:
    25350479
  • 财政年份:
    2013
  • 资助金额:
    $ 24.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Comparative Effectiveness of Basic and Advanced Life Support in Ambulances
救护车中基本和高级生命支持的效果比较
  • 批准号:
    8656271
  • 财政年份:
    2013
  • 资助金额:
    $ 24.89万
  • 项目类别:
EAGER: US IGNITE: An Application-Aware, Cross-Layer Design for Audio-Visual Applications in Medical Ambulances
EAGER:US IGNITE:医疗救护车中视听应用的应用感知跨层设计
  • 批准号:
    1258290
  • 财政年份:
    2012
  • 资助金额:
    $ 24.89万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了